Relay Therapeutics, Inc. Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAY

Classificação em ações #4224
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$17.16
Última sincronização: 2026-10-19
Valor de mercado
$3.76B
Variação (1 dia)
5.41%
Variação (1 ano)
140.34%
País
US
Negociar Relay Therapeutics, Inc. (RLAY)

Categoria

Healthcare
Histórico de rendimento de dividendos para Relay Therapeutics, Inc. (RLAY)
O rendimento de dividendos (TTM) da Relay Therapeutics, Inc. (símbolo da ação: RLAY) em 2023-12-31 é: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Relay Therapeutics, Inc. (RLAY) de 2018 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL